Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma.

Authors :: Song YQ
Zhang HL
Huang HQ
Zhang QY
Jing HM
Wang C
Wu C
Li DH
Dai Y
Humphrey K
Zhu J
Source :: Haematologica [Haematologica] 2024 Apr 01; Vol. 109 (4), pp. 1269-1273. Date of Electronic Publication: 2024 Apr 01.
Publication Year :: 2024

Subjects :: Humans
China
Lymphoma, Non-Hodgkin
Lymphoma, Large B-Cell, Diffuse drug therapy
Lymphoma, Large B-Cell, Diffuse pathology
Antibodies, Bispecific

Full Text Access

Tools